- Home
- FMY vs HOWL Comparison
FMY vs HOWL Comparison
Compare FMY & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMY
- HOWL
- Stock Information
- Founded
- FMY 2005
- HOWL 2017
- Country
- FMY United States
- HOWL United States
- Employees
- FMY N/A
- HOWL N/A
- Industry
- FMY Finance/Investors Services
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- FMY Finance
- HOWL Health Care
- Exchange
- FMY Nasdaq
- HOWL Nasdaq
- Market Cap
- FMY 50.5M
- HOWL 47.1M
- IPO Year
- FMY N/A
- HOWL 2021
- Fundamental
- Price
- FMY $12.19
- HOWL $1.36
- Analyst Decision
- FMY
- HOWL Strong Buy
- Analyst Count
- FMY 0
- HOWL 3
- Target Price
- FMY N/A
- HOWL $8.33
- AVG Volume (30 Days)
- FMY 10.1K
- HOWL 554.2K
- Earning Date
- FMY 01-01-0001
- HOWL 08-07-2025
- Dividend Yield
- FMY 6.98%
- HOWL N/A
- EPS Growth
- FMY N/A
- HOWL N/A
- EPS
- FMY N/A
- HOWL N/A
- Revenue
- FMY N/A
- HOWL $1,143,000.00
- Revenue This Year
- FMY N/A
- HOWL N/A
- Revenue Next Year
- FMY N/A
- HOWL N/A
- P/E Ratio
- FMY N/A
- HOWL N/A
- Revenue Growth
- FMY N/A
- HOWL N/A
- 52 Week Low
- FMY $10.71
- HOWL $0.60
- 52 Week High
- FMY $12.17
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- FMY 51.72
- HOWL 60.96
- Support Level
- FMY $12.19
- HOWL $1.25
- Resistance Level
- FMY $12.28
- HOWL $1.44
- Average True Range (ATR)
- FMY 0.06
- HOWL 0.10
- MACD
- FMY -0.01
- HOWL 0.02
- Stochastic Oscillator
- FMY 43.48
- HOWL 68.89
About FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield and maturity.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.